{"id":3041,"date":"2026-09-09T08:00:00","date_gmt":"2026-09-09T12:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3041"},"modified":"2026-09-10T19:57:36","modified_gmt":"2026-09-10T23:57:36","slug":"march5-complex-defines-a-venetoclax-sensitization-interface","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3041","title":{"rendered":"MARCH5 Complex Defines a Venetoclax-Sensitization Interface"},"content":{"rendered":"

Evidence<\/strong> Peer-reviewed publication · Discovery<\/strong> September 10, 2026 · Importance<\/strong> 4\/5 · Direction<\/strong> Uncertain<\/p>\n

\"MARCH5<\/p>\n

Summary<\/h4>\n

A Blood study identified a stress-responsive complex formed by the mitochondrial E3 ligase MARCH5, UBE2J2 and MFN2 at mitochondria-endoplasmic-reticulum contact sites. Genetic loss of MARCH5 lowered the apoptotic threshold and sensitized multiple blood-cancer models to BCL-2 and BCL-XL inhibitors. Disruption of specific protein-protein interactions restored BH3-mimetic sensitivity in cytokine-protected primary chronic lymphocytic leukemia cells and prolonged survival in a refractory lymphoma mouse model. The mechanism is translationally interesting for venetoclax resistance, but no drug-like MARCH5 inhibitor, human pharmacology or clinical efficacy was demonstrated.<\/p>\n

What Happened<\/h4>\n

The authors used genetic dependency and mechanistic experiments to place MARCH5, UBE2J2 and MFN2 in a spatially organized stress-sensing axis. The complex colocalized with BCL-2 and BCL-XL, but not MCL-1, at contact sites between mitochondria and the endoplasmic reticulum. Organellar damage caused complex dissociation before BAX and BAK activation, linking stress sensing to the commitment step in mitochondrial apoptosis. MARCH5 or UBE2J2 deletion resensitized primary chronic lymphocytic leukemia cells made BH3-mimetic resistant by cytokine exposure. Across nonhematopoietic cell lines, the dependency was more restricted to BCL-XL, which the authors interpret as a basis for tissue-selective combinations.<\/p>\n

Deep Analysis<\/h4>\n

A tractable combination target:<\/strong> The convergence of genetic dependency, spatial mechanism, primary-cell resensitization and in-vivo survival benefit supports MARCH5-complex disruption as more than a screening artifact. A mutation-agnostic venetoclax sensitizer could be relevant in AML, myeloma, CLL and other BCL-2-dependent malignancies. Counterevidence is the absence of selective chemical matter, exposure-response data and proof that partial pharmacologic inhibition reproduces genetic deletion without unacceptable mitochondrial toxicity.<\/p>\n

A vulnerability with a narrow therapeutic window:<\/strong> MARCH5 regulates mitochondrial homeostasis beyond malignant cells, so the same stress-threshold effect could amplify toxicity in normal hematopoietic or other high-demand tissues. The apparent hematologic selectivity may reflect the tested models or BCL-2-family context. Conversely, interaction-specific inhibition rather than wholesale MARCH5 blockade could preserve essential functions and create a combination window.<\/p>\n

Signal Extraction<\/h4>\n

Verified facts: online-ahead-of-print peer-reviewed publication; genetically defined MARCH5-UBE2J2-MFN2 complex; blood-cancer sensitization to BCL-2 and BCL-XL inhibitors; primary CLL-cell resensitization; survival extension in a refractory lymphoma mouse model. Missing facts: quantitative therapeutic index, normal-HSC effects, druggability and human biomarkers. Upgrade evidence would be a selective small molecule that produces target engagement, venetoclax synergy and marrow-sparing efficacy in multiple in-vivo models.<\/p>\n

Company and Product Background<\/h4>\n

The work was led by investigators at the Walter and Eliza Hall Institute of Medical Research and collaborating Australian centers. It is an academic target-discovery program rather than a disclosed clinical asset; a public technology summary indicates the team is pursuing high-throughput, fragment and DNA-encoded-library screening and is seeking partners or investment for an oral small-molecule inhibitor.<\/p>\n

Venetoclax inhibits BCL-2 and is a backbone in AML and CLL, but adaptive survival signaling and apoptotic-threshold changes can limit depth and durability. MARCH5 is a mitochondrial outer-membrane E3 ubiquitin ligase; the reported complex with UBE2J2 and MFN2 sits at mitochondria-ER contact sites and restrains stress-induced apoptosis, creating a potential synthetic-lethal relationship with BCL-2-family inhibition.<\/p>\n

InSilens Take<\/h4>\n

The paper elevates MARCH5 from a recurrent dependency hit to a spatially defined apoptosis-control mechanism with candidate protein interfaces. Its strongest near-term value is as a drug-discovery map for reversing BH3-mimetic resistance, not as evidence that MARCH5 inhibition is already a viable therapy. The decisive work is chemical: selective engagement, normal-tissue tolerance and combination activity at clinically realistic exposures. Until then, importance is high for mechanism and partnering potential, while direction remains uncertain.<\/p>\n

Signal Assessment<\/h4>\n\n\n\n\n\n
Signal Importance<\/strong><\/td>\n4 \/ 5 — defines a potentially druggable, mutation-agnostic route to deepen or restore venetoclax responses in blood cancers<\/td>\n<\/tr>\n
Signal Direction<\/strong><\/td>\nUncertain — the mechanism is constructive, but pharmacologic feasibility and therapeutic window are unproven<\/td>\n<\/tr>\n
Confidence in Facts<\/strong><\/td>\nHigh — core findings reported in a peer-reviewed Blood article with primary-cell and in-vivo support<\/td>\n<\/tr>\n
Confidence in Interpretation<\/strong><\/td>\nModerate-low — translation depends on selective chemical matter, normal-tissue safety and reproducible combination efficacy<\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

A Blood study identified a stress-responsive complex formed by the mitochondrial E3 ligase MARCH5, UBE2J2 and MFN2 at mitochondria-endoplasmic-reticulum contact sites. Genetic loss of MARCH5 lowered the apoptotic threshold and sensitized multiple blood-cancer models…<\/p>\n","protected":false},"author":1,"featured_media":3043,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[701,700,699,467,245],"class_list":["post-3041","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology-modalities","tag-apoptosis","tag-bcl-2","tag-march5","tag-venetoclax","tag-wehi"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3041","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3041"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3041\/revisions"}],"predecessor-version":[{"id":3061,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3041\/revisions\/3061"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3043"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3041"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3041"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3041"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}